Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Digestive enzymes in the intestinal lumen are a collective group of hydrolases, including pancreatic lipases, amylases, and proteases, as well as brush border enzymes like alpha-glucosidases, which are essential for the breakdown of dietary macronutrients into absorbable molecules (StatPearls, 2023, NBK544242). These enzymes play a pivotal role in nutrient homeostasis, and their deficiency leads to malabsorption syndromes such as exocrine pancreatic insufficiency (EPI), often associated with cystic fibrosis or chronic pancreatitis (NIH, NIDDK, 2022). In therapeutic contexts, these enzymes are targeted either through replacement therapy, using porcine-derived pancrelipase to restore digestive function, or through pharmacological inhibition (StatPearls, 2023, NBK534814). For example, orlistat inhibits gastric and pancreatic lipases to reduce fat absorption for obesity management, while alpha-glucosidase inhibitors like acarbose delay carbohydrate digestion to manage postprandial glycemia in type 2 diabetes (PubChem, CID 3033049; PubChem, CID 41774). Consequently, these enzymes are critical targets for managing both metabolic disorders and gastrointestinal health.
The mechanism of action involves either the exogenous supplementation of enzymes (pancrelipase) to catalyze the hydrolysis of fats, proteins, and starches in the duodenum, or the competitive inhibition of specific enzymes to modulate nutrient uptake. Lipase inhibitors (e.g., orlistat) covalently bond to the active site of gastric and pancreatic lipases, preventing the hydrolysis of dietary triglycerides into absorbable free fatty acids (PubChem, CID 3033049). Alpha-glucosidase inhibitors (e.g., acarbose) competitively inhibit enzymes at the brush border of the small intestine, slowing the release of glucose from complex carbohydrates and smoothing postprandial blood glucose curves (PubChem, CID 41774).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Digestive enzymes in the intestinal lumen.